Differential retention of rhodamine 123 by breast carcinoma and normal human mammary tissue.

abstract：PURPOSE:To evaluate the loco-regional recurrence (LRR) rate after breast-conserving surgery without postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast. METHODS:Between 2000 and 2010, 311 DCIS patients from 9 institutions were analyzed retrospectively. The median age was 47 (range, 20-82)...

journal_title：Breast cancer research and treatment

authors： Kim K,Jung SY,Shin KH,Kim JH,Han W,Lee HB,Huh SJ,Choi DH,Park W,Ahn SD,Kim SS,Kim JH,Suh CO,Kim YB,Kim IA,Kim S,Kim YJ

更新日期：2017-02-01 00:00:00

abstract：:Paraneoplastic neurological syndromes are a rare complication of breast cancer. Nevertheless, they may be clinically relevant leading to neurological impairment. Clinicians should be aware that these neurological disorders could even precede the diagnosis of breast cancer. Here we present the case of a female patient ...

journal_title：Breast cancer research and treatment

authors： Minisini AM,Pauletto G,Bergonzi P,Fasola G

更新日期：2007-10-01 00:00:00

abstract：PURPOSE:To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing. METHODS:Data included 20,758 women from Dr. Susan Love Research Foundation's The Health of Women (HOW)...

journal_title：Breast cancer research and treatment

authors： Silver MI,Klein W,Samimi G,Minasian L,Loud J,Roberts MC

更新日期：2019-02-01 00:00:00

abstract：:Bone lesions as a consequence of bone metastases in breast cancer patients can increase risk for skeletal-related events (SREs) (i.e., radiation to the bone, a pathological or osteoporotic fracture event, hypercalcemia, spinal cord compression, or surgery to the bone). The mortality risk for breast cancer patients wit...

journal_title：Breast cancer research and treatment

authors： Yong M,Jensen AÖ,Jacobsen JB,Nørgaard M,Fryzek JP,Sørensen HT

更新日期：2011-09-01 00:00:00

abstract：:EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

journal_title：Breast cancer research and treatment

authors： Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

更新日期：2011-06-01 00:00:00

abstract：PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

journal_title：Breast cancer research and treatment

authors： Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

更新日期：2020-01-01 00:00:00

abstract：:Estrogen plus progestin hormone therapy has been associated with increased breast proliferation, breast density, and breast cancer risk in postmenopausal women, beyond that seen with estrogen alone. The goal of this study was to evaluate progestogen effects on gene expression profiles in the breast contributing to thi...

journal_title：Breast cancer research and treatment

authors： Wood CE,Register TC,Cline JM

更新日期：2009-03-01 00:00:00

abstract：:A human estrogen receptor (ER) cDNA probe was used to examine genomic DNA extracted from 59 primary invasive breast cancers. The tumors were also studied histopathologically, and their ER status was assessed by hormone-binding assay and immunohistochemical analysis. Southern blots of genomic DNA samples digested with ...

journal_title：Breast cancer research and treatment

authors： Parl FF,Cavener DR,Dupont WD

更新日期：1989-10-01 00:00:00

abstract：:Recently, many centers have omitted routine axillary lymph node dissection (ALND) after metastatic sentinel node biopsy in breast cancer due to a growing body of literature. However, existing guidelines of adjuvant treatment planning are strongly based on axillary nodal stage. In this study, we aim to develop a novel ...

journal_title：Breast cancer research and treatment

authors： Meretoja TJ,Audisio RA,Heikkilä PS,Bori R,Sejben I,Regitnig P,Luschin-Ebengreuth G,Zgajnar J,Perhavec A,Gazic B,Lázár G,Takács T,Kővári B,Saidan ZA,Nadeem RM,Castellano I,Sapino A,Bianchi S,Vezzosi V,Barranger E,L

更新日期：2013-04-01 00:00:00

abstract：:In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor sa...

journal_title：Breast cancer research and treatment

authors： Bevilacqua P,Verderio P,Barbareschi M,Bonoldi E,Boracchi P,Dalla Palma P,Gasparini G

更新日期：1996-01-01 00:00:00

abstract：:Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

journal_title：Breast cancer research and treatment

authors： Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

更新日期：2015-11-01 00:00:00

abstract：:Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab trea...

journal_title：Breast cancer research and treatment

authors： Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T

更新日期：2012-06-01 00:00:00

abstract：PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

journal_title：Breast cancer research and treatment

authors： Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

更新日期：2019-11-01 00:00:00

abstract：:Mammographic density is a strong and independent risk factor for breast cancer and is considered an intermediate marker of risk. The major predictors of premenopausal mammographic density, however, have yet to be fully elucidated. To test the hypothesis that urinary estrogen metabolism profiles are associated with mam...

journal_title：Breast cancer research and treatment

authors： Bertrand KA,Eliassen AH,Hankinson SE,Gierach GL,Xu X,Rosner B,Ziegler RG,Tamimi RM

更新日期：2012-11-01 00:00:00

abstract：:We report the establishment of a breast epithelial cell model that undergoes growth arrest at different stages of the cell cycle depending upon the DNA damaging agents encountered. Primary breast epithelial cells from normal reductive mammoplasty were grown in low-calcium culture medium. Free-floating cells under this...

journal_title：Breast cancer research and treatment

authors： Shen KC,Miller F,Tait L,Santner SJ,Pauley R,Raz A,Tainsky MA,Brooks SC,Wang YA

更新日期：2006-08-01 00:00:00

abstract：:The NSABP B-30 trial addresses whether amenorrhea after adjuvant chemotherapy increases survival. Preliminary to the trial outcome analysis, we examined the incidence of amenorrhea and its relationship to symptoms and quality of life (QOL) in the standard-care arm of this adjuvant breast cancer trial. Premenopausal wo...

journal_title：Breast cancer research and treatment

authors： Swain SM,Land SR,Ritter MW,Costantino JP,Cecchini RS,Mamounas EP,Wolmark N,Ganz PA

更新日期：2009-01-01 00:00:00

abstract：:Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant "window of opportunity" study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin ...

journal_title：Breast cancer research and treatment

authors： Niraula S,Dowling RJ,Ennis M,Chang MC,Done SJ,Hood N,Escallon J,Leong WL,McCready DR,Reedijk M,Stambolic V,Goodwin PJ

更新日期：2012-10-01 00:00:00

abstract：:Axillary evaluation in women with ductal carcinoma in situ (DCIS) is increasing; however, this may introduce additional morbidity with unclear benefit. Our objective was to examine the morbidity and mortality associated with axillary evaluation in DCIS. We conducted a retrospective cohort study of 10,504 women aged 65...

journal_title：Breast cancer research and treatment

authors： Coromilas EJ,Wright JD,Huang Y,Feldman S,Neugut AI,Hillyer GC,Chen L,Hershman DL

更新日期：2016-07-01 00:00:00

abstract：:Feulgen-stained samples from 460 small (pT1) primary breast cancers were investigated by means of an image analysis system. Several DNA, morphometrical and textural parameters were evaluated for each patient, and the prognostic meaning of these parameters was then investigated by the Cox regression analysis. As progno...

journal_title：Breast cancer research and treatment

authors： Aubele M,Auer G,Falkmer U,Voss A,Rodenacker K,Rutquist LE,Höfler H

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:As the number of survivors continues to increase with improvements in breast cancer treatment, greater emphasis has been placed on the aesthetic outcome following breast surgery. Effort is made to minimize scarring on the breast, yet patients who require a port for treatment inevitably have a scar on the upper ...

journal_title：Breast cancer research and treatment

authors： Voci A,Lee D,Ho E,Crane-Okada R,DiNome M

更新日期：2018-08-01 00:00:00

abstract：:We previously identified a polymorphism in the human estrogen receptor (ER) gene, within the coding region for the protein's amino terminal B-domain. In estrogen receptor-positive (ER+) breast tumors, the variant allele was preferentially associated with lower levels of ER, and was clinically correlated with frequent ...

journal_title：Breast cancer research and treatment

authors： Schmutzler RK,Sanchez M,Lehrer S,Chaparro CA,Phillips C,Rabin J,Schachter B

更新日期：1991-10-01 00:00:00

abstract：:The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip, Roche that facilitates the classification of individuals by testing 27...

journal_title：Breast cancer research and treatment

authors： Ramón y Cajal T,Altés A,Paré L,del Rio E,Alonso C,Barnadas A,Baiget M

更新日期：2010-01-01 00:00:00

abstract：:Resistance of breast cancers to targeted hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) inhibitors often occurs through dysregulation of the phosphoinositide 3-kinase, protein kinase B/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Presently, no targeted therapies exist for breast...

journal_title：Breast cancer research and treatment

authors： Wilson-Edell KA,Yevtushenko MA,Rothschild DE,Rogers AN,Benz CC

更新日期：2014-04-01 00:00:00

abstract：:The ErbB2 receptor is a proto-oncogene associated with a poor prognosis in breast cancer. Herceptin, the only humanized anti-ErbB2 antibody currently in clinical use, has proven to be an essential tool in the immunotherapy of breast carcinoma, but induces cardiotoxicity. ErbB2 is involved in the growth and survival pa...

journal_title：Breast cancer research and treatment

authors： Fedele C,Riccio G,Malara AE,D'Alessio G,De Lorenzo C

更新日期：2012-07-01 00:00:00

abstract：:Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost...

journal_title：Breast cancer research and treatment

authors： Safonov A,Wang S,Gross CP,Agarwal D,Bianchini G,Pusztai L,Hatzis C

更新日期：2016-01-01 00:00:00

abstract：:Breast cancer is the most common malignant tumor-affecting women during the child bearing period. With the rising trend in delaying pregnancy later in life, the issue of subsequent pregnancy and lactation following breast cancer diagnosis has been more frequently encountered. In this context, data is scarce particular...

journal_title：Breast cancer research and treatment

authors： Azim HA Jr,Bellettini G,Gelber S,Peccatori FA

更新日期：2009-03-01 00:00:00

abstract：:Serum melatonin (MLT) levels have been reported to diminish significantly by the 5th and 6th decades of life as the incidence of breast cancer increases. Given MLT's anti-cancer activity, we hypothesize that age-related decline in pineal MLT production leads to enhanced breast cancer development and growth as women ag...

journal_title：Breast cancer research and treatment

authors： Hill SM,Cheng C,Yuan L,Mao L,Jockers R,Dauchy B,Frasch T,Blask DE

更新日期：2011-05-01 00:00:00

abstract：AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

journal_title：Breast cancer research and treatment

authors： Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

更新日期：2001-04-01 00:00:00

abstract：:Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

journal_title：Breast cancer research and treatment

authors： Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

更新日期：2007-04-01 00:00:00

abstract：:Paclitaxel is a highly active single agent as therapy for previously untreated as well as doxorubicin-refractory metastatic breast cancer, with associated response rates of 62% and 20-48%, respectively. Complete responses with paclitaxel occur chiefly in breast cancer patients whose metastatic disease has not been pre...

journal_title：Breast cancer research and treatment

authors： O'Shaughnessy JA,Cowan KH

更新日期：1995-01-01 00:00:00